277 related articles for article (PubMed ID: 16723549)
1. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.
Kiser TH; Hoody DW; Obritsch MD; Wegzyn CO; Bauling PC; Fish DN
Antimicrob Agents Chemother; 2006 Jun; 50(6):1937-45. PubMed ID: 16723549
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
[TBL] [Abstract][Full Text] [Related]
3. Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.
Burgess DS; Hall RG
Clin Ther; 2007 Jul; 29(7):1421-7. PubMed ID: 17825693
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
Frei CR; Burgess DS
Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of levofloxacin in critically ill patients with ventilator-associated pneumonia.
Benko R; Matuz M; Doro P; Peto Z; Molnar A; Hajdu E; Nagy E; Gardi J; Soos G
Int J Antimicrob Agents; 2007 Aug; 30(2):162-8. PubMed ID: 17570646
[TBL] [Abstract][Full Text] [Related]
6. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
Conte JE; Golden JA; McIver M; Zurlinden E
Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
[TBL] [Abstract][Full Text] [Related]
7. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis.
Deguchi T; Nakane K; Yasuda M; Shimizu T; Monden K; Arakawa S; Matsumoto T
Int J Antimicrob Agents; 2010 Jun; 35(6):573-7. PubMed ID: 20226636
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis.
Nicolle L; Duckworth H; Sitar D; Bryski L; Harding G; Zhanel G
Int J Antimicrob Agents; 2008 Mar; 31(3):287-9. PubMed ID: 18155885
[TBL] [Abstract][Full Text] [Related]
9. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
Conte JE; Golden JA; McIver M; Little E; Zurlinden E
Int J Antimicrob Agents; 2007 Nov; 30(5):422-7. PubMed ID: 17716873
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats.
Albarellos GA; Ambros LA; Landoni MF
J Vet Pharmacol Ther; 2005 Aug; 28(4):363-9. PubMed ID: 16050816
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
[TBL] [Abstract][Full Text] [Related]
12. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
Walters T; Rinehart M; Krebs W; Holdbrook M
Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
[TBL] [Abstract][Full Text] [Related]
13. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
Noreddin AM; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the pharmacokinetic disposition of levofloxacin in stallions after intravenous and intramuscular administration.
Goudah A; Abo El-Sooud K; Shim JH; Shin HC; Abd El-Aty AM
J Vet Pharmacol Ther; 2008 Oct; 31(5):399-405. PubMed ID: 19000258
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.
Sprandel KA; Drusano GL; Hecht DW; Rotschafer JC; Danziger LH; Rodvold KA
Diagn Microbiol Infect Dis; 2006 Aug; 55(4):303-9. PubMed ID: 16887471
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
